The Centers for Disease Control and Prevention (CDC), a federal agency responsible for public health guidance in the United States, has seen a slowdown in its process for recommending vaccines over the past year. This has raised questions about how the public will receive timely and accurate health guidance. One notable example is the mFlusiva flu vaccine, which was recently approved by the Food and Drug Administration (FDA) for use in adults aged 50 to 64. Despite this approval, the CDC has not yet recommended it for use, which is unusual given the agency's typical practices. Efforts to change vaccine recommendations by officials in the Trump administration have been put on hold, and discussions on new vaccine policies have decreased. Health Secretary Robert F. Kennedy Jr. has made several changes to vaccine policy, including reducing the number of vaccines recommended for children, which have faced legal challenges. These changes have disrupted established systems for delivering health guidance, potentially affecting the availability of vaccines that protect against serious diseases. Jason Schwartz, a health policy researcher at Yale University, notes that a lack of a clear process for making changes to vaccine policy has led to a standstill, even when strong evidence supports new recommendations. The Advisory Committee on Immunization Practices (ACIP), which had guided the CDC’s vaccine recommendations for 60 years, was disbanded by Kennedy and replaced with a group that included individuals with anti-vaccine views. This change led to controversial decisions and a lawsuit from the American Academy of Pediatrics and other medical groups. A federal judge recently ruled that Kennedy likely violated federal procedures, halting his panel’s meetings and suspending his decision to reduce the number of vaccines recommended for children. While many in the medical community welcomed this as a pause to what they saw as a threat to vaccines, the overall process has become stalled and fragmented. In response, doctors’ groups have started debating vaccine policies privately and issuing their own recommendations. Many of these align with previous CDC and ACIP guidelines, though some updates have been made, such as extending the RSV vaccine recommendation for pregnant women to March instead of January.